We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Low-Dose Colchicine Reduces Myocardial Infarction and Stroke Risk in Cardiovascular Disease Patients

MedXY Editorial Team•Dec 16, 2025•Cardiology
cardiovascular diseasecolchicinemyocardial infarctionSecondary Prevention

Highlights

  • High-certainty evidence supports low-dose colchicine in reducing myocardial infarction and stroke risk in patients with established cardiovascular disease.
  • No increase in serious adverse events was observed, but gastrointestinal side effects were more common.
  • No significant reduction in all-cause or cardiovascular mortality, or coronary revascularisation rates.
  • Further research is needed to clarify benefits in specific subgroups and long-term use in stable coronary artery disease.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Impact of Age at Type 1 Diabetes Onset on Mortality and Organ Complications: Insights from a Nationwide Swedish CohortYounger age at type 1 diabetes diagnosis significantly increases risks of mortality, cardiovascular, and kidney complications; each additional year delay in onset reduces these risks. This review synthesizes nationwide cohort findings and cSep 23, 2026Identifying and Mitigating Risk Factors for Intracranial Haemorrhage Following Tenecteplase Fibrinolysis in Acute Myocardial InfarctionThis study evaluates risk factors for intracranial haemorrhage after tenecteplase fibrinolysis in STEMI patients, developing a prediction model highlighting age, blood pressure, sex, weight, and dose interactions as key determinants.Sep 23, 2026Efficacy and Safety of Semaglutide According to Frailty Status: Insights from the SELECT Randomized Clinical Trial Post Hoc AnalysisSemaglutide demonstrates consistent cardiovascular benefits and safety across frailty levels in overweight adults with cardiovascular disease, enhancing quality of life and frailty status without increased adverse events.Sep 21, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Inpatient Rehabilitation and Major Adverse Cardiovascular Events After Ischemic Stroke: Clinical Implications and Evidence Synthesis
Postacute discharge to inpatient rehabilitation facilities (IRF) after acute ischemic stroke (AIS) is associated with a reduced 1-year risk of major adverse cardiovascular events (MACE) compared to discharge to home or skilled nursing facil
Sep 19, 2026
Targeting the CCND1-PDK4 Axis to Promote Reparative Macrophage Phenotype and Mitigate Post-Myocardial Infarction Cardiac RemodelingThis article discusses the role of cyclin D1 (CCND1) in promoting reparative macrophage transition post-myocardial infarction, highlighting its therapeutic potential in reducing adverse cardiac remodeling through metabolic reprogramming.Sep 19, 2026
Evaluating Targeted Vitamin D Supplementation Post-Myocardial Infarction: Insights from the TARGET-D TrialThe TARGET-D trial investigated whether vitamin D supplementation, titrated to achieve serum levels >40-80 ng/mL, reduces major adverse cardiovascular events after myocardial infarction but found no significant benefit in the primary comSep 17, 2026